Quick Answer
RHYTHM PHARMACEUTICALS, INC. reported R&D Expense of $167.34 million for fiscal year 2025.
RHYTHM PHARMACEUTICALS, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $167.34M | -29.7% |
| 2024 | $237.96M | +76.3% |
| 2023 | $134.95M | +24.2% |
| 2022 | $108.63M | +4.3% |
| 2021 | $104.13M | +15.1% |
| 2020 | $90.45M | -17.4% |
| 2019 | $109.45M | +117.4% |
| 2018 | $50.34M | +119.9% |
| 2017 | $22.89M | +16.8% |
| 2016 | $19.59M | +174.1% |
| 2015 | $7.15M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $46.03M | +21.3% | +8.8% |
| June 30, 2025 | $42.31M | +40.1% | +14.4% |
| March 31, 2025 | $36.97M | -71.3% | -2.5% |
| September 30, 2024 | $37.93M | +13.0% | +25.6% |
| June 30, 2024 | $30.19M | -10.0% | -76.5% |
| March 31, 2024 | $128.66M | +239.1% | +283.3% |
| September 30, 2023 | $33.57M | +59.0% | +0.1% |
| June 30, 2023 | $33.54M | +6.6% | -11.6% |
- RHYTHM PHARMACEUTICALS, INC. showed a decrease of -29.7% in R&D Expense compared to the prior fiscal year.
- Over the 2015–2025 period, RHYTHM PHARMACEUTICALS, INC.’s r&d expense has grown by 2241.1% (from $7.15 million to $167.34 million).
- The most recent figure is from RHYTHM PHARMACEUTICALS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: